Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care
- 18 February 2010
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 11 (4), 373-382
- https://doi.org/10.1016/s1470-2045(09)70341-9
Abstract
No abstract availableKeywords
This publication has 80 references indexed in Scilit:
- Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trialBritish Journal of Cancer, 2009
- A role for VEGF as a negative regulator of pericyte function and vessel maturationNature, 2008
- Preoperative Tyrosine Kinase Inhibition as an Adjunct to Debulking NephrectomyUrology, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- Targeted drugs for metastatic renal cell carcinomaThe Lancet, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma PatientsCancer Cell, 2007
- Molecular regulation of vessel maturationNature Medicine, 2003
- Abnormal blood vessel development and lethality in embryos lacking a single VEGF alleleNature, 1996